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Intensive breeding and selection on desired traits have produced high rates of inherited diseases in dogs. Hereditary retinal
degeneration, often called progressive retinal atrophy (PRA), is prevalent in dogs with disease entities comparable to human
retinitis pigmentosa (RP) and Leber’s congenital amaurosis (LCA). Recent molecular studies in the English Springer Spaniel (ESS)
dog have shown that PRA cases are often homozygous for a mutation in the RPGRIP1 gene, the defect also causing human RP,
LCA, and cone rod dystrophies. The present study characterizes the disease in a group of aﬀected ESS in USA, using clinical,
functional, and morphological studies. An objective evaluation of retinal function using electroretinography (ERG) is further
performed in a masked fashion in a group of American ESS dogs, with the examiner masked to the genetic status of the dogs. Only
4 of 6 homozygous animals showed clinical signs of disease, emphasizing the need and importance for more precise studies on the
clinical expression of molecular defects before utilizing animal models for translational research, such as when using stem cells for
therapeutic intervention.
1.Introduction
The domestic dog has a unique population history with
bottlenecks that has shaped the diversity and structure of
the canine genome. The ﬁrst bottleneck can be traced back
about 7,000–50,000 generations [1] and reﬂects the early
domestication of dogs from wild populations of wolves
15,000–100,000 years ago [2–4]. When dog breeds were
established in the 1800s (about 50–100 generations ago)
more genetic variation was lost, and this second population
bottleneck resulted in relatively large genetic diﬀerences
between breeds and little genetic variation within breeds.
The two bottlenecks left distinctive signatures in the canine
genome with long-range linkage disequilibrium (LD) and
long haplotype blocks of 500kb–1Mb within breeds and
short-range LD across breeds [1, 5]. Intensive breeding and
selection on desired traits have also produced high rates of
inherited diseases with genetic causes that are breed-speciﬁc
or nearly so. The domestic dog has therefore emerged as an
important animal model for comparative genome analysis
and for characterization of inherited disease. Other uses
for dog models are in translational research such as gene
therapy or stem cell transplantation for treatment strategies
in conjunction with hereditary retinal blinding diseases.2 Stem Cells International
Hereditary retinal degeneration, often called progressive
retinal atrophy (PRA) in dogs and also in cats, is a group of
diseases of the photoreceptors that exists in various forms.
Rods and cones are usually primarily aﬀected, with time
leading to bilateral blindness. More than 100 dog breeds are
on the list for those that may be aﬀected, in which at least
15 mutations are prevalent in 34 speciﬁc dog breeds [6].
For cats, PRA is observed less frequently, although recently,
a mutation in the CEP290 gene was shown to be causative
of hereditary retinal degeneration in a large number of cat
breeds, primarily Abyssinian and Siamese cats [7].
Through advancement in the understanding of hered-
itary disease processes aﬀecting the outermost portion of
the retina, PRA has been further characterized biochem-
ically, electrophysiologically, morphologically, and geneti-
cally. Using molecular methods, including the elucidation of
causative mutant genes for several hereditary retinal disor-
ders, much knowledge has been gained especially in regards
to disease mechanisms [8]. The availability of the canine
genome sequence [1]( http://www.genome.gov/12511476)
has simpliﬁed the task of identifying genes responsible for
diseases and traits in dogs. Similarly, a full genome sequence
(10X) of the cat has recently been completed (Wes Warren,
Washington University, personal communication, 2010). A
number of the PRAs have been designated gene symbols
reﬂecting either the speciﬁc cells involved in the hereditary
retinal dystrophy or the protein involved in the retinal
degenerative condition.
Although PRA is usually manifested with a breed speciﬁc
phenotype, the same allelic mutation may be shared by
several diﬀerent breeds, such as for the prcd mutation [9].
In other instances, diﬀerent but allelic mutations causative
of PRA have been documented in related breeds [10].
Importantly, breeds may also express more than one form
of PRA. For example, in golden retrievers at least three
diﬀerent genes and mutations are responsible for PRA.
Two of the genes are known, prcd and slc4a3, but at
least one more gene remains to be characterized [11].
T h ep r e s e n c eo fm o r et h a no n ec a u s a t i v em u t a t i o nf o r
PRA in some breeds is complicating the understanding
and interpretation of phenotype-genotype relationships and
thus the results of DNA testing procedures [12]. Due to
these factors, phenotypic heterogeneity is often found when
studying various forms of retinal degenerative diseases of
dogs. This has also been observed in similar retinal disease
processes of humans, such as in retinitis pigmentosa (RP)
or in Leber’s congenital amaurosis (LCA). In these diseases,
signiﬁcant phenotypic heterogeneity is found including age
of onset, clinical ﬁndings, and progression of disease [8,
13]. This is especially true for RP in which at least 140
mutations have been described only in the rhodopsin gene
[14, http://omim.org/entry/268000].
Classical PRA has been described as a generalized disease
ofthefundus,aﬀectingtherodphotoreceptorsprimarilyand
with later involvement of cones. Clinically night blindness
is an early sign but with progression of disease, aﬀection of
both night and day vision occurs. Ophthalmoscopically early
changes have been noted as a generalized diﬀu s ec h a n g ei n
colorationandreﬂectivityofthetapetalfunduswithvascular
attenuation in later stages, the changes being most severe in
the peripheral parts but with later involvement of the entire
fundus [15].
PRA in the English Springer Spaniel dog was originally
described in USA [16]. There were some unusual ﬁndings
in the disease in that there was an increased granularity
of the fundus or a slightly patchy discoloration as the
earliest clinical sign observed in the very far periphery of the
tapetal fundus. The disease had a variable time of onset and
progression,leadingtoblindnessinmostoftheaﬀecteddogs.
Mutations in the RPGRIP1 gene have been identiﬁed
as causative to human RP, LCA, and cone-rod dystrophies
[17–19]. The RPGRIP1 protein was shown to be involved in
transport mechanisms that occur through the photoreceptor
connecting cilium by interaction with another protein,
RPGR [20]. Defects in the latter gene are responsible for the
X-linked retinopathy of humans and also in X-linked PRA in
Samoyed and Siberian husky dogs [21]. Further, a mutation
in NPHP4, another gene known to interact with RPGRIP1,
was shown to be causative of cone/rod dystrophy of the
wire-haired Dachshund [22, 23]. Another such gene working
in concert with RPGRIP1 is CEP290, and when mutated it
was found to cause hereditary retinal degeneration in cats
[24]. The protein is also an important component of the
transport mechanism, whereby specialized proteins critical
for phototransduction are transferred from their site of
synthesisintheinnersegmentthroughtheconnectingcilium
to the outer segment [25] .An u m b e ro fn o r m a lg e n e sa r e
thus necessary for normal function and structure of the
entire photoreceptor cell and, especially, for outer segment
disc morphogenesis [26].
Mellersh and collaborators recently mapped the cone
rod locus (cord1) to a 14.5Mb region on dog chromosome
15 (16.54–30.68Mb: coordinates as in CanFam2.0), which
contained the RPGRIP1 gene. A 44bp insertion in exon 2
was further identiﬁed in the RPGRIP1 gene, truncating the
protein. This defect segregated completely with the cord1
phenotype of cone rod dystrophy in the Animal Health Trust
(UnitedKingdom)researchcolonyofminiaturedachshunds.
It was concluded that the mutation was responsible for cord1
disease, due to a mutation in the RPGRIP1 gene. It was
further emphasized that dogs with this disease are valuable
animal models for exploring disease mechanisms and poten-
tial therapies for the human counterpart, LCA [27].
The RPGRIP1 mutation in cone rod dystrophy (cord1)
was further evaluated as a candidate gene for PRA in ESS
dogs using DNA collected at the University of Missouri
(Columbia, USA), from a large number of dogs, unaﬀected
and aﬀected by bilateral, generalized retinal degeneration.
The mutation was observed in exon 2 of RPGRIP1 in all of
the aﬀected dogs (Gary Johnson and Liz Hansen, personal
communications, 2007).
This paper describes the results of a research project that
was thereafter initiated, in order to characterize the clinical
signs of retinal degeneration in the ESS breed and to evaluate
thegenotype-phenotypecorrelationinUSAinfamily-owned
ESS, in regards to the mutation in the RPGRIP1 gene.
Recently, the study was further expanded to also include
blood samples from a group of Swedish ESS dogs, with andStem Cells International 3
Table 1: Swedish ESS dogs with genotype-phenotype correlation in regards to the RPGRIP1 mutation. The sex of the dogs is indicated as M
for males and F for females. The age of diagnosis is shown as years (y) and months (m) when dogs were ﬁrst examined and diagnosed with
PRA. For the dogs without PRA (normal), the most recent examination dates were used for age at examination. The genotypes are given as
−/− for genetically aﬀected, +/− for carriers, and +/+ for genetically clear individuals of the 44bp deletion in exon 2 of the RPGRIP1 gene.
Dog number Sex Age at examination Phenotype RPGRIP1 genotype
ESS-008 M 2y 4m PRA −/−
ESS-014 F 3y 8m PRA −/−
ESS-004 F 5y 9m PRA +/−
ESS-006 M 5y 7m PRA +/−
ESS-016 M 7y 3m PRA +/−
ESS-020 M 9y 8m PRA +/−
ESS-003 F 5y 4m PRA +/+
ESS-005 F 3y 1m PRA +/+
ESS-007 M 11y 4m PRA +/+
ESS-009 M 4y 6m PRA +/+
ESS-015 F 8y 3m Normal +/+
ESS-017 F 5y 11m Normal +/+
ESS-018 F 12y 1m Normal +/+
ESS-019 M 7y 10m Normal +/+
without clinical signs of PRA and the correlation in regards
to the RPGRIP1 mutation.
2.MaterialsandMethods
2.1. Animals and Clinical Examinations. ESS dogs from
USA were included in the characterization of disease. They
were privately owned dogs for which owners or breeders
had requested eye examinations, according to eye scheme
routines, since their dogs or their close relatives were used
for breeding. Twelve cases with clinical signs of retinal
degeneration in 1.5- to 12-year-old ESS dogs were discovered
during the two-year study period. All of the aﬀected dogs
were homozygous for the RPGRIP1 mutation.
Informed consent was obtained from the owners of
participating dogs. The clinical study included evaluation
of retinal and vision based responses and reﬂexes: menace,
dazzle, and examination of the pupillary light reﬂexes as
well as visual testing by behavior and visual reactions to
fallingcottonballs[28].Pupilsweredilatedwithshort-acting
mydriatics 20 minutes before examination of the internal
structures, using 1-2 drops of 1% tropicamide in each eye
(Mydriacyl, Bausch and Lomb Inc., Tampa, FL). Standard
ophthalmic examination of the interior of the eye was then
performed using indirect ophthalmoscopy (Welch-Allyn
Distributors, Medical Device Depot, Inc., MD, USA) and slit
lamp biomicroscopy (SL14, KOWA Co. Ltd., Tokyo, Japan).
Fundus appearance was documented with a digital fundus
camera (Nidek NM-100, Nidek Co. Ltd., Freemont, CA).
2.2. DNA Samples. DNA samples from ESS dogs previously
collectedbyDr.GaryJohnson’slaboratory,UniversityofMis-
souri, Columbia, USA, were utilized. All samples were col-
lectedassurplusfrombloodspecimenssubmittedforroutine
cord1 test or for clinical biochemistry under the condition
of anonymity of the individuals and their owners. DNA was
extracted from blood samples and genotyping for the cord1
disease causing allele of the mutated gene RPGRIP1 gene was
performed as described by Mellersh et al., 2006 [27].
In addition, to investigate whether the cord1 genotype
was prevalent among ESS dogs in Sweden, and especially in
ESS dogs diagnosed with PRA, blood samples from a total
of 14 normal and aﬀected dogs were tested for the 44bp
insertioninexon2oftheRPGRIP1gene(Table 1).Theblood
from the Swedish dogs was collected into EDTA tubes and
genomicDNAwasextractedmanuallyfromperipheralblood
leukocytes using QIAamp DNA Blood Midi Kit (Qiagen,
Hilden, Germany) or automatically on a QIA symphony
SP/AS instrument (Qiagen, Hilden, Germany).
Primers for genotyping the 44bp insertion in exon2 of
RPGRIP1 gene were designed using the software Primer3
[29]. PCR ampliﬁcation was performed using the primers
Cfa Cord1-F (5 -6FAM-CCCTTTCCTGGGACTTTAGG-3 )
and Cfa Cord1-R (5 -CCCTCTGCCTATGTCTCTGC-3 ).
10–20ng of genomic DNA was used in a 10uL PCR-reaction
with 0.5mM of each primer, 50mM KCl, 10mM Tris-HCl
pH 8.3, 2.5mM MgCl2, 0.2mM of each dNTP and 0.5 units
of Taq polymerase (AmpliTaq Gold; Applied Biosystems,
Foster City, CA, USA; DNA polymerase). A total of 35 PCR
cycles was performed, each with denaturation at 94◦Cf o r1
minute, annealing at 60◦C for 40s and a primer extension
at 72◦C for 40s. The fragment length polymorphism was
then determined using an ABI 3100 DNA Analyzer and
GeneMapper Software (Applied Biosystems, Inc., (ABI),
Foster City, CA).
2.3. Masked Electroretinography Study. Fourteen American
dogs were included in a masked electroretinography (ERG)
study for objective evaluation of retinal function (for ERG
see details below). Blood from these dogs, age between
7y 9m and 13y 10m, had previously been genotyped by
Dr. Johnson’s laboratory, as described above. Dogs were4 Stem Cells International
Table 2: Details in regards to dogs in the masked ERG study. The genotypes are given as −/− for genetically aﬀected, +/− for carriers, and
+/+ for genetically clear individuals of the 44bp deletion in exon 2 of the RPGRIP1 gene. The age at the time for ophthalmic and ERG
examinations is given as years (y) and months (m).
Dog number RPGRIP1 genotype Age at ERG ERG results Other clinical ﬁndings
1 −/− 9y 2m Abnormal Normal vision, fundus normal
2+ / − 8y 7m Normal Normal vision, fundus normal
3+ / − 7y 9m Normal Normal vision, fundus normal
4+ / − 7y 9m Normal Normal vision, fundus normal
5+ / − 13y 10m Normal Normal vision, fundus normal
6+ / − 11y 11m Normal Normal vision, fundus normal
7 −/− 9y 2m Abnormal Normal vision, fundus abnormal
8 −/− 9y 2m Abnormal Normal vision, fundus abnormal
9 −/− 8y 4m Normal Normal vision, fundus normal
10 +/− 9y 4m Normal Normal vision, fundus normal
11 +/− 8y Normal Normal vision, fundus normal
12 +/+ 9y 3m Normal Normal vision, fundus normal
13 −/− 12y 4m Abnormal Reduced vision, fundus abnormal
14 −/− 7y Normal Normal vision, fundus normal
chosen for retinal functional evaluation in accordance with
the owner’s consent and availability. The genetic status
of each dog in regards to the RPGRIP1 mutation was
unknown to the investigator (K. Narfstr¨ om) at the time of
the ERG recordings: 6 dogs were homozygous (aﬀected);
RPGRIP−/−, 7 were heterozygous (normal); RPGRIP−/+,
and 1 was homozygous (normal); RPGRIP1+/+ (Table 2).
Before the ERG was performed in each dog, they underwent
a routine ophthalmic examination as previously described.
2.4. Electroretinography. Unilateral electroretinographic
(ERG) evaluations were performed using a portable ERG
unit (HMsERG model 1000, RetVet Corp., Columbia, MO),
with a mini-Ganzfeld dome positioned approximately 1cm
from the right tested eye (Figure 1). For practical reasons
it was deemed suﬃcient to perform the evaluation in only
o n ee y es i n c eb o t he y e sa r eu s u a l l ya ﬀected in hereditary
retinopathies and the eyes are usually at the same stage
of the retinal degenerative process [15]. Dogs were deeply
sedated by using medetomidine IV (Domitor, Novartis,
Pﬁzer Animal Health, Exton, PA), up to 150 micrograms/kg,
equivalent to 0.15mL/kg, and prepared for the ERG session
in ordinary room light. Heart and respiratory rates were
closely monitored before and throughout the procedure
and the dogs were temperature controlled. The dog’s head
was positioned on a cushion for stabilization. Maximal
pupillary dilation was provided for by the use of short-acting
mydriatics (see above) and the eye was further topically
anesthetized using 0.5% proparacaine hydrochloride
(Alcaine, Alcon, Fort Worth, TX). A lid speculum was
inserted to ensure that the nictitating membrane as well
as the upper and lower eyelids did not interfere with
light exposure to the maximally dilated pupils. Platinum
subdermal needle electrodes (model E2, Grass Instrument
Division, Astro-Med, Inc., West Warwick, RI) were used
for the ground electrode, positioned on the occipital crest,
and for the reference electrode, positioned 3cm from the
Figure 1: An English Springer Spaniel (ESS) dog deeply sedated
and prepared for functional evaluation of the retina. The handheld
multispecies electroretinograph (HMsERG) unit is used together
with a preprogrammed protocol for evaluation of rod and cone
function.
lateral canthus, close to the base of the right ear. An active
contact lens electrode (ERG-Jet, Universo Plastique, LKC
Technologies Inc., Gaithersburg, Md) was placed on the
cornea after instillation of one drop of 2% methylcellulose
(Methocel, Ciba Vision, Munich, Germany). The electrodes
were connected to a preampliﬁer and the signals were
ampliﬁed with a bandpass ﬁlter between 0.3 and 300Hz.
Each ERG session consisted of scotopic and photopic
ERGs in accordance with the “Dog Diagnostic Protocol,”
recommended by the European College of Veterinary Oph-
thalmologists, primarily for evaluation and separation of rod
and cone function [30]. This protocol is preprogrammed on
the ERG unit and is executed automatically upon initiation
of the ERG session by the examiner. During 20 minutesStem Cells International 5
of dark adaptation, scotopic-low intensity rod responses
were elicited every 4 minutes at a stimulus intensity of
0.01cd·s/m2; responses were averaged after 10 ﬂashes given
at 2 seconds interval and rod responses were recorded at
each time point (test #1–5). The light stimulus intensity was
then increased to 3cd·s/m2 for scotopic standard intensity
stimulation and responses averaged and recorded after 4
ﬂashes at 10-second intervals (test #6). Thereafter scotopic
high-intensity responses were elicited using 10cd·s/m2;
responses were averaged to 4 ﬂashes administered at 20-
second intervals (test #7). The latter two recordings depict
a mixture of responses from both rods and cones. After 10
minutes of light adaptation with a background luminance
of 30cd/m2, photopic single ﬂash responses were recorded,
using 3cd·s/m2 of ﬂash stimulus, averaging 32 ﬂashes at an
interval of 0.5 seconds (test #8), followed by evaluation of
30Hz photopic ﬂicker at the same light intensity stimulation
(test #9). The latter two recordings were performed in order
to evaluate cone and cone pathways, respectively. Data were
collected automatically on the compact ﬂash card of the
ERG unit, transferred to a computer, printed, and stored for
further analysis. ERGs were evaluated and the amplitudes
and implicit times for the a- and b-waves were measured as
previously described [30].
After termination of the ERG session an injection of
atipamazole hydrochloride (Antisedan, Pﬁzer Inc., St Louis,
MO) was administered intramuscularly to reverse the deep
sedation (at a dosage 5-times higher than that given of the
medetomidine, i.e., similar volumes were injected).
2.5. Morphology. Upon the owner’s request due to unrelated
medicalproblems,threeAmericanESSdogswereeuthanized
and the eye tissue made available for the present study.
Advanced PRA had been diagnosed in two of the dogs (9 and
6 years old, resp.), while the third dog, 3 years old, had a nor-
mal fundus appearance. Euthanasia was performed by intra-
venous infusion of Beuthanasia-D-Special (Schering Plough
AnimalHealth,Omaha,NE.).Theeyesofeachdogwereenu-
cleated immediately after death and the posterior segment
of each eye placed in ﬁxative solution for examination using
light and electron microscopy (LM and EM). The ﬁxative
included 2.0% glutaraldehyde, 1.12% paraformaldehyde,
0.13Msodiumcacodylate,0.13mMCaCl2,pH7.40.Eyecups
were incubated with gentle agitation for at least 2 hours at
room temperature. The eyecups were then gross sectioned
to obtain 2 × 3mm pieces from the following regions: the
central part of the fundus, temporal to the optic nerve head
(the area centralis-like region), superior midperiphery and
periphery, and inferior midperiphery and periphery. Sam-
ples from these regions were postﬁxed in 1% osmium tetrox-
ide and embedded in epoxy resin. They were washed with
0.17M sodium cacodylate, pH 7.4, followed by secondary
ﬁxation in 1% osmium tetroxide. Subsequently, the samples
were dehydrated via sequential incubation in increasing
concentrations of acetone and embedded in epoxy resin.
Sections of the embedded samples were cut for both LM
andEMexaminations.ForLM,1-micron-thicksectionswere
mounted on glass slides and stained with toluidine blue. For
EM,sectionsweremountedoncoppergridsandwerestained
∗
Figure 2: A composite of fundus pictures from a two-year-old
ESS dog aﬀected with cone rod dystrophy and homozygous for
the RPGRIP1 mutation. The central fundus is mainly normal
appearing while an increase in granularity is observed in the
midperipheral and peripheral fundus (star). There is also slight
vascular attenuation with variable diameter of retinal vasculature
(arrows).
withuranylacetateandleadcitrate.LMwasperformedusing
a Zeiss Axiophot microscope and EM was performed using a
JEOL 1200 EX transmission electron microscope.
2.6. Statistical Evaluations. Descriptive statistics were per-
formed in relation to the masked ERG study using the SAS
v9 (SAS Institute Inc. Cary, NC, USA) of the dogs classiﬁed
as normal (including homozygous normal and heterozygous
dogs) and aﬀected dogs by DNA analysis for the RPGRIP1
mutation. Due to the small sample size in the aﬀected group
and the fact that the data did not show any extreme outliers,
two-sample t-tests with the Satterthwaite approximation for
degrees of freedom allowing for unequal variances between
the groups were utilized. Due to the marked diﬀerences
between the groups, resultswereconsidered signiﬁcant at the
0.01 signiﬁcance level.
3. Results
3.1. Clinical Characterization of Retinal Degeneration due to
the RPGRIP1 Mutation. A 10-year-old dog was examined
due to severe visual problems reported by the owner, ﬁrst
noted at the age of 8 years. Advanced signs of retinal
degeneration were observed by ophthalmoscopy in this dog.
None of the other 11 dogs examined with clinical signs of
retinal disease (ophthalmoscopic changes or reduced ERG
responses) had shown visual problems until the age of 6–9
years, according to the owners.
The earliest ophthalmoscopic signs of disease were
observed in a 1.5- and a 2-year-old ESS dog, respectively.
Both showed increased granularity in the far peripheral
tapetal fundus, with minute hyporeﬂective brown to gray
spots in the far periphery of the tapetal fundus (Figure 2).
With increasing age (in 3–8-year-old dogs) these abnor-
malities became more generalized with diﬀuse mottling6 Stem Cells International
of the tapetal fundus and changes in fundus coloration.
There was also generalized changes in tapetal reﬂectivity
(hyporeﬂectivity and with movement of the lens used for
indirect ophthalmoscopy, some of these areas became hyper-
reﬂective).Atthislaterstagetherewasalsosevereattenuation
of retinal vasculature. At 9-10 years of age, a generalized,
end-stage type of retinal degeneration was observed in most
aﬀected dogs with a marked hyperreﬂective tapetal area,
severe attenuation of retinal vasculature with few vessels
still visible, mainly in the central parts of the fundus. At
this stage there was also decoloration interspersed with
hyperpigmentationofthenontapetalfundus.One9-year-old
dog had a mainly normal fundus appearance although ERG
examination showed reduced responses for both the cone
and the rod system. Bilateral, secondary cataracts (complete
and immature types) were observed at age 12 years in
one of the clinically aﬀected dogs described in the present
study.
3.2. Genotype-Phenotype Evaluation in Swedish ESS. Blood
from 14 dogs was included in the study in which ten of the
dogs had been diagnosed with PRA. Two cases of PRA were
found to be homozygous for the disease causing RPGRIP
allele (−/−), four were genotyped as heterozygous (+/−)
and four of the cases had the homozygous genotype for the
normal allele (+/+) (Table 1).
3.3. Masked ERG Study. A marked reduction of ERG
responses was observed in 4 of 6 of the dogs that had
been diagnosed as homozygous for the RPGRIP1 mutation
through blood testing (Table 2). Three of the 4 dogs eval-
uated as aﬀe c t e db yE R G sh a dn o ts h o w na n ya p p a r e n t
deﬁciency in vision as evaluated by the owner or by the
examiner.Twoofthesedogshadnormalfundusappearances,
while the other two dogs had early and moderately advanced
r e t i n a ld e g e n e r a t i v ec h a n g e s ,r e s p e c t i v e l y .T h et w od o g s ,
homozygous for the RPGRIP mutation that had normal
ERGs, were also ophthalmoscopically normal.
Results of ERG recordings in a normal 8-year-old ESS
and in two aﬀected dogs, 9 and 12 year olds, respectively,
are shown in Figure 3. Evaluation of a-wave amplitudes
showed signiﬁcant diﬀerences between the aﬀected group
and the heterozygous and homozygous normal group, at the
0.01 signiﬁcance level, when scotopic and photopic standard
intensity responses were compared (P<0.0004 and P<
0.0007, resp.). For the b-wave these diﬀerences were also
signiﬁcant at the same level for 4 of the 5 scotopic low-
intensity responses evaluated (#2–5) (P<0.0084, 0.0003,
0.0005, and 0.0020, resp.) and for the photopic ﬂicker
response (P<0.0032). For a- and b-wave implicit times
there were no signiﬁcant diﬀerences for the former while for
the latter a signiﬁcant longer implicit time was found for the
aﬀected group of dogs in comparison to the normal group
for scotopic standard intensity stimulation (P<0.0066). For
ERG amplitude and implicit time details see Table 3.
T w od o g si nt h eg r o u p ,f o u n dt ob eh o m o z y g o u sf o r
the RPGRIP1 mutation by blood testing, had a- and b-wave
amplitude and implicit time values that were in complete
accordance with the normal group of dogs.
In order to evaluate if the cone system was more aﬀected
than the rod system by the disease, the percentage reduction
for each was calculated. This was performed through com-
parison of the median response from aﬀected and normal
dogs, respectively, using photopic standardintensity (test#8)
and photopic ﬂicker responses (test #9) for the cone system
and scotopic low-intensity stimulation (test #5) for the rod
system. It was found that the cone system was more aﬀected
than the rod system: 46% and 58% reduction, respectively,
for the cones and 44% reduction for the rods in the aﬀected
group when compared with the normal ESS group of dogs.
3.4. Morphology. Light and electron microscopies were per-
formed using retinal sections from 3 dogs. The two older
dogs had ophthalmoscopic signs of severe bilateral gener-
alized retinal degeneration while the younger, a 3-year-old
ESS dog, exhibited a granular but otherwise normal fundus
appearance. DNA from the youngest dog only was obtained,
and showed homozygocity for the RPGRIP1 mutation.
In the 9-year-old dog, bilaterally atrophic retinas with no
residual photoreceptor cells and sporadic remnants of cells
from inner nuclear and ganglion cell layers were observed,
with marked retinal gliosis (Figures 4 and 5).
The retinas of the second dog, 6-years-old, showed signs
of bilateral generalized retinal degeneration, with complete
atrophy of the inferior retina, and a lack of photoreceptor
cells in this area, while in the superior retina 1-2 layers of
photoreceptor nuclei could be observed.
The 3-year-old dog, however, demonstrated mainly
normal retinal morphology except for changes in the pho-
toreceptor cell layer at all retinal locations examined: cone
cell nuclei appeared slightly abnormal, with dense chromatin
and with photoreceptor inner segments condensed and
shrunken (Figure 6). Photoreceptor outer segments could
not be clearly visualized in the thin sections obtained, and
thus their ultrastructure was not possible to fully evaluate.
4. Discussion
The present study indicates that a majority of the American
ESS dogs with hereditary retinal degeneration can be
associated with homozygosity for the disease causing
allele of the RPGRIP1 g e n e .H o w e v e r ,f o u ro ft h e6d o g s
homozygous for the RPGRIP1 mutation had clinical signs
of disease while 2 were completely normal appearing both
by ophthalmoscopic examination and by ERG. Thus, a clear
genotype-phenotype discordance was observed in regards to
this group of ESS dogs.
A large proportion of the genetically and/or clinically
aﬀected dogs did not show signs of visual impairment until
comparably late in life and 2 were clinically completely
normal. The reason for the latter ﬁnding is unclear. It could
be that the RPGRIP1 insertion by itself is not suﬃcient to
cause retinal degeneration. It appears likely that additional
factors are warranted for initiation of photoreceptor cell
death such as additional loci involved as modiﬁers of the
disease, as have been described for various forms of PRA, for
example, prcd and X-linked PRA [9, 31]. It could possibly
alsobethatthereisnotfullpenetranceforthemutation[32].Stem Cells International 7
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Figure 3: Scotopic and photopic ERGs from a normal 8-year-old ESS dog and two RPGRIP1−/− aﬀected ESS dogs at the age of 9 (aﬀected
1) and 12 years (aﬀected 2), respectively. The latter aﬀected dog was normal at ophthalmoscopic examination when it was 9 years old.
At the age of 12 years it was only slightly visually compromised, and in a moderately advanced stage of retinal degeneration as seen by
ophthalmoscopy. S5: scotopic ERG response using 10mcd·s/m2 of light stimuli after 20 minutes of dark adaptation, Ssd: scotopic ERG
response using 3cd·s/m2 of light stimuli in the dark, Psd: photopic ERG response using 3cd·s/m2 in the light after 10 minutes of light
adaptation (with 30cd/m2 of background light), Pﬂ: photopic ERG ﬂicker response after 30Hz ﬂickering light stimuli in the light adapted
state.
Similar ﬁndings have been observed in comparable
human clinical studies in cone rod dystrophies and degen-
erations. A phenotypic variation between clinical signs in
aﬀected individuals and in the onset of hereditary retinal
dystrophies has been observed, also by functional testing
in human cone rod dystrophies [33]. The variation in
clinical signs and time for initial symptoms is especially
true for retinopathies caused by the RPGRIP1 mutation,
on a variable genetic background, such as is the case in
the human population. In purebred dogs, however, a more
uniform phenotype is usually expressed, due to a more
homogenous background. This fact is true for most forms
of PRA; however, for the cone-rod dystrophies observed
in the longhaired and shorthaired Dachshund breeds, with
the RPGRIP1 and NPHP4 mutations, respectively, severe
heterogeneity has been described for both [22, 27, 34].
In retinal degeneration of the ESS dog clinical signs most
often appear comparably late in life and are often diﬃcult
to evaluate by the owner. For most of the aﬀected dogs
observed in the present study the owners had not noted any
visual impairment. The owner of an 11-year-old dog from
the present study described that the dog could still play with8 Stem Cells International
Table 3: ERG amplitude and implicit time for normal and aﬀected ESS dogs in the masked study. Median, 5th and 95th percentiles are
given for ERG a- and b-wave amplitudes (a) in microvolts and in (b) for implicit times in milliseconds, for normal and aﬀected ESS dogs.
Scotopic ERGs consisted of scotopic low-intensity responses (S: 0.01cd·s/m2), which were elicited 4, 8, 12, 16, and 20 minutes after dark
adaptation designated: S1, S2, S3, S4, and S5, scotopic standard intensity responses, Ssd: 3cd·s/m2, and scotopic higher intensity responses,
Sh: 10cd·s/m2. Photopic ERGs consisted of a photopic single ﬂash response: Psd, and 30Hz ﬂicker responses: Pﬂ, using 3cd·s/m2 for both,
after at least 10 minutes of light adaptation using 30cd/m2 of background light.
(a)
Response Wave
Normal Aﬀected
Median 5th 95th Median 5th 95th
S1 b 29.8 16.7 53.1 20.4 15.0 34.0
S2 b 61.6 40.2 101.3 37.7 35.4 45.0
S3 b 98.4 73.9 116.3 52.1 39.4 61.2
S4 b 122.8 78.8 146.4 56.2 50.9 71.2
S5 b 137.3 86.5 185.0 75.0 53.4 85.8
Ssd a 128.1 102.1 181.9 29.0 16.9 64.9
b 196.5 138.7 261.6 146.5 72.5 186.0
Sh a 162.3 137.4 236.8 38.1 23.5 86.9
b 240.5 171.7 307.7 169.4 77.6 230.8
Psd a 8.3 3.9 11.5 3.0 2.5 3.6
b 30.8 13.8 35.0 15.4 6.6 24.9
Pﬂ b 34.1 15.4 47.5 15.0 6.9 22.6
(b)
Response Wave
Normal Aﬀected
Median 5th 95th Median 5th 95th
S1 b 63.5 57.2 87.1 81.0 65.7 87.7
S2 b 75.8 69.2 92.4 84.5 78.5 91.7
S3 b 78.7 75.0 92.3 81.4 76.9 89.8
S4 b 82.3 73.6 95.3 80.3 76.3 96.0
S5 b 80.6 74.8 94.9 86.2 77.3 94.3
Ssd a 14.3 12.5 15.4 13.5 12.3 15.7
b 32.7 31.3 59.5 196.5 138.7 261.6
Sh a 12.6 11.3 13.7 13.3 10.1 15.0
b 46.9 32.6 52.4 240.5 171.7 307.7
Psd a 10.6 10.0 12.0 10.0 9.0 12.8
b 21.6 20.0 23.5 30.8 13.8 35.0
Pﬂ b 21.5 20.4 24.8 34.1 15.4 47.5
(a) (b)
Figure 4: (a) Light microscopy (LM) of the inferior nontapetal retina of the 9-year-old ESS dog. Severe thinning of the entire retina is seen
with complete degeneration of photoreceptor cells and inner retinal degeneration, disorganization, and gliosis. (b) LM of superior tapetal
retina. A variation in retinal thickness is observed and some areas with a single row of photoreceptor nuclei that are still present. Toluidine
blue staining; ×40.Stem Cells International 9
(a) (b)
Figure 5: Ultrastructure of nontapetal (a) and tapetal retina (b) from the same dog shown in Figure 4. Note the severely disorganized outer
and inner retinal cell layers and structures. The RPE cell layer appears preserved, however. In (b) there is relative sparing of the retina with
someminorremnantsofphotoreceptornucleiwithinnersegments(arrow)andanabundanceofRPEapicalmicrovilli.RPE:retinalpigment
epithelial cells, T: tapetal cells. Bar depicts magniﬁcation which is the same for (a) and (b).
(a) (b)
Figure 6: Ultrastructure of the outer retina of a normal 2-year-old dog (a) and that of the aﬀected 3-year-old dog (b). Note the condensed
conﬁguration of the cone nuclei in the retina of the aﬀected animal (arrow) in comparison to that of the normal one (in (a), arrow) and the
dark appearance of the inner segments in the retina of the aﬀected animal. Bar depicts magniﬁcation which is the same for (a) and (b).
a transparent frisbee and could easily walk down an indoor
stairwayinlow-lightingconditions.Thisdoghadmoderately
advanced retinal degeneration with ophthalmoscopically
visible changes and was homozygous for the RPGRIP1
mutation. Another dog showing clinical signs of retinal
degeneration had been diagnosed as ophthalmoscopically
normal by a veterinary ophthalmologist one year previously,
attheageof7years.ERGsshowed,however,severelyreduced
retinal function in accordance with a cone rod dystrophy.
It is likely that the cone aﬀection in the disease is
early onset, and a defect the dog learns to live with as
long as its rod function is normal. Morphology of one 3-
year-old ESS dog, homozygous for the RPGRIP1 mutation,
showed ultrastructural changes speciﬁcally in cones, while
rod photoreceptors were still normal appearing. It is possible
that the visual problems become apparent clinically later
in life when also the rods start to degenerate. Further, this
second phase appears to occur at a variable time point, but10 Stem Cells International
most often not until late in life, then leading to a rather fast
generalized severe retinal degeneration (retinal atrophy).
ERG recordings proved to be useful in the masked
study of the present investigation for objectively detecting
reduced photoreceptor function in accordance with cone
rod dystrophy due to the RPGRIP1 mutation. In two cases,
however, function in genetically aﬀected individuals was
found to be within normal limits. These discordant clinical
results could be consistent with incomplete penetrance for
the mutation, but other factors previously outlined may also
be involved.
Other aﬀected genes or other mutations in RPGRIP1
may also be present in the ESS breed. One mutated
gene, prevalent in at least 32 canine breeds, is prcd,
(http://www.optigen.com/, 2011). This could also be a
candidate gene since it is known to aﬀect the English and
American Cocker Spaniel dog breeds, distant relatives to
the ESS dog (Liz Hansen, personal communication 2006).
Some of the other mutations causing primary photoreceptor
d e g e n e r a t i o n si nd o g sa r eA D A M 9[ 35], CCDC66 [36],
CNGB3 [37], RD3 [38], RHO [39], RPE65 [40], VMD2 [41],
PDE6beta [42], PDE6A [43], and PDC [44].
Among the ten PRA cases in ESS dogs previously
diagnosed in Sweden, from which DNA was available for
the current study, only two individuals were homozygous for
the disease causing allele at the RPGRIP1 locus. Four were
found to be heterozygous and four were homozygous for
the normal wild-type allele (Table 1). The two cases being
homozygousfortheRPGRIP1insertionwerediagnosedwith
PRA at two and four years of age, respectively. Although
the number of cases is small there appears to be a tendency
for a later onset of PRA among the other eight cases. None
of the normal dogs were found to be homozygous for the
RPGRIP1 insertion in the Swedish samples, but to make
any inferences about the penetrance, a much larger data set
would be needed. Taken together, the study of the Swedish
samples suggests that at least one more gene is responsible
for PRA in the Swedish population.
T h ec o m p l e t ea s s o c i a t i o nb e t w e e nRPGRIP1 and PRA
observedintheESSthusremainstobefullyelucidated.There
are strong indications that the RPGRIP1 gene is involved in
the cone rod dystrophy described herein, but the genotype-
phenotype discordance observed shows that the genetic
background most probably is more complex than previously
suspected. In conclusion, there are strong indications that
other mutations or modulating genes may be involved in
coneroddystrophyofESSdogsandcouldalsobecausativeto
other types of hereditary retinal degenerations in the breed.
Further investigations in regards to additional loci or genes
required for development of cord1 are therefore warranted.
An important goal for vision research is to provide
eﬀective treatments for the millions of people aﬀected with
retinal blinding disorders. Therapeutic intervention using
large animal models such as dogs and cats are eﬀective and
necessary methods to utilize before proceeding with human
treatment trials. Proof of principle was obtained through
therapeutic studies using gene therapy in a dog model
of LCA [45], resulting in successful restoration of vision.
Similar procedures were performed in human patients with
successful outcome [46, 47]. Another promising therapeutic
method for retinal blinding disease is stem cell therapy, with
or without combination of gene therapy [48]. In preparation
for such studies it is, however, of utmost importance that
the animal model with its speciﬁc retinal disease is precisely
characterized clinically beforehand, and with molecular
methods, for maximal outcome in the translational process.
Acknowledgments
The authors would like to thank the breeders and owners
of English Springer Spaniel dogs for participation in eye
examinations with their dogs, which made this study pos-
sible. Dr. Gary S. Johnson and Liz Hansen provided DNA
from ESS dogs from their genetics department data bank for
the masked study, which is gratefully acknowledged. They
would also like to thank Leilani Castaner, Howard Wilson
and Davida Myrby for outstanding technical assistance. This
paper has been ﬁnanced by the American Kennel Club, the
joint research fund of Agria and the Swedish Kennel Club,
and the English Springer Spaniel breeding clubs in Sweden
and in USA.
References
[1] K. Lindblad-Toh, C. M. Wade, T. S. Mikkelsen et al., “Genome
sequence, comparative analysis and haplotype structure of the
domestic dog,” Nature, vol. 438, no. 7069, pp. 803–819, 2005.
[ 2 ]J .A .L e o n a r d ,R .K .W a y n e ,J .W h e e l e r ,R .V a l a d e z ,S .G u i l l´ en,
and C. Vil` a, “Ancient DNA evidence for old world origin of
New World dogs,” Science, vol. 298, no. 5598, pp. 1613–1616,
2002.
[3] P. Savolainen, Y. P. Zhang, J. Luo, J. Lundeberg, and T. Leitner,
“Genetic evidence for an East Asian origin of domestic dogs,”
Science, vol. 298, no. 5598, pp. 1610–1613, 2002.
[4] B. M. Vonholdt, J. P. Pollinger, K. E. Lohmueller et al.,
“Genome-wide SNP and haplotype analyses reveal a rich
history underlying dog domestication,” Nature, vol. 464, no.
7290, pp. 898–902, 2010.
[ 5 ]E .K .K a r l s s o n ,I .B a r a n o w s k a ,C .M .W a d ee ta l . ,“ E ﬃcient
mapping of mendelian traits in dogs through genome-wide
association,” Nature Genetics, vol. 39, no. 11, pp. 1321–1328,
2007.
[6] S. Petersen-Jones, “Advances in the molecular understanding
of canine retinal diseases,” Journal of Small Animal Practice,
vol. 46, no. 8, pp. 371–380, 2005.
[7] M. Menotti-Raymond, V. A. David, A. A. Sch¨ aﬀer et al.,
“Mutation in CEP290 discovered for cat model of human
retinal degeneration,” Journal of Heredity,v o l .9 8 ,n o .3 ,p p .
211–220, 2007.
[8] A. I. den Hollander, R. Roepman, R. K. Koenekoop, and F. P.
M. Cremers, “Leber congenital amaurosis: genes, proteins and
disease mechanisms,” Progress in Retinal and Eye Research, vol.
27, no. 4, pp. 391–419, 2008.
[9] B. Zangerl, O. Goldstein, A. R. Philp et al., “Identical
mutation in a novel retinal gene causes progressive rod-cone
degeneration in dogs and retinitis pigmentosa in humans,”
Genomics, vol. 88, no. 5, pp. 551–563, 2006.
[10] G. Dekomien, M. Runte, R. G¨ odde, and J. T. Epplen,
“Generalized progressive retinal atrophy of Sloughi dogs is
due to an 8-bp insertion in exon 21 of the PDE6B gene,”Stem Cells International 11
Cytogenetics and Cell Genetics, vol. 90, no. 3-4, pp. 261–267,
2000.
[11] L. M. Downs, B. Wallin-H˚ akansson, M. Boursnell et al., “A
frameshiftmutationinGoldenRetrieverdogswithprogressive
retinal atrophy endorses SLC4A3 as a candidate gene for
human retinal degenerations,” PLoS ONE,v o l .6 ,n o .6 ,a r t i c l e
e21452, 2011.
[12] M. B. Jeong, C. H. Han, K. Narfstr¨ om et al., “A phosducin
(PDC) gene mutation does not cause progressive retinal
atrophy in Korean miniature schnauzers,” Animal Genetics,
vol. 39, no. 4, pp. 455–456, 2008.
[13] E. M. Stone, “Leber congenital amaurosis—a model for
eﬃcient genetic testing of heterogeneous disorders. LXIV
Edward Jackson Memorial Lecture,” American Journal of
Ophthalmology, vol. 144, no. 6, pp. 791–811, 2007.
[14] E. M. Stone, “Finding and interpreting genetic variations that
are important to ophthalmologists,” Transactions of the Amer-
ican Ophthalmological Society, vol. 101, pp. 437–484, 2003.
[15] K. Narfstr¨ om and S. Petersen-Jones, “Diseases of the canine
ocularfundus,”inVeterinaryOphthalmology,K.N.Gelatt,Ed.,
vol. 2, pp. 944–1025, Blackwell Publishing, 4th edition, 2007.
[16] J. Hyman, S. A. Koch, J. P. Pickett, and S. Estep, “A unique
retinal degenerative disease in the English Springer Spaniel; a
continued prospective study,” in Proceedings of the European
College of Veterinary Ophthalmology Stockholm Meeting, p. 34,
2001.
[17] T. P. Dryja, S. M. Adams, J. L. Grimsby et al., “Null RPGRIP1
alleles in patients with Leber congenital amaurosis,” American
JournalofHumanGenetics,vol.68,no.5,pp.1295–1298,2001.
[18] A. Hameed, A. Abid, A. Aziz, M. Ismail, S. Q. Mehdi, and S.
Khaliq,“EvidenceofRPGRIP1genemutationsassociatedwith
recessive cone-rod dystrophy,” Journal of Medical Genetics, vol.
40, no. 8, pp. 616–619, 2003.
[19] J. C. Booij, R. J. Florijn, J. B. ten Brink et al., “Identiﬁcation
of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and
RPGRIP1genesinpatientswithjuvenileretinitispigmentosa,”
Journal of Medical Genetics, vol. 42, no. 11, p. e67, 2005.
[20] R. Roepman, N. Bernoud-Hubac, D. E. Schick et al., “The
retinitis pigmentosa GTPase regulator (RPGR) interacts with
novel transport-like proteins in the outer segments of rod
photoreceptors,” Human Molecular Genetics, vol. 9, no. 14, pp.
2095–2105, 2000.
[21] Q. Zhang, G. M. Acland, W. X. Wu et al., “Diﬀerent RPGR
exon ORF15 mutations in Canids provide insights into
photoreceptor cell degeneration,” Human Molecular Genetics,
vol. 11, no. 9, pp. 993–1003, 2002.
[22] E. O. Ropstad, K. Narfstr¨ om, F. Lingaas, C. Wiik, A. Bruun,
and E. Bjerkas, “Functional and structural changes in the
retina of wirehaired dachshunds with early onset cone-rod
dystrophy,” Investigative Ophthalmology & Visual Science, vol.
49, no. 3, pp. 1106–1115, 2008.
[23] A.C.Wiik,C.Wade,T.Biagietal.,“Adeletioninnephronoph-
thisis 4 (NPHP4) is associated with recessive cone-rod dys-
trophy in standard wire-haired dachshund,” Genome Research,
vol. 18, no. 9, pp. 1415–1421, 2008.
[24] K. Narfstr¨ om, K. Holland Deckman, and M. Menotti-
Rymond, “The domestic cat as a large animal model for
characterization of disease and therapeutic intervention in
hereditary retinal blindness,” Journal of Ophthalmology, vol.
2011, Article ID 906943, 8 pages, 2011.
[25] G. J. Pazour, S. A. Baker, J. A. Deane et al., “The intraﬂagellar
transport protein, IFT88, is essential for vertebrate photore-
ceptor assembly and maintenance,” Journal of Cell Biology, vol.
157, no. 1, pp. 103–113, 2002.
[26] Y. Zhao, D. H. Hong, B. Pawlyk et al., “The retinitis pigmen-
tosaGTPaseregulator(RPGR)-interactingprotein:subserving
RPGR function and participating in disk morphogenesis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 7, pp. 3965–3970, 2003.
[27] C. S. Mellersh, M. E. G. Boursnell, L. Pettitt et al., “Canine
RPGRIP1 mutation establishes cone-rod dystrophy in minia-
ture longhaired dachshunds as a homologue of human Leber
congenital amaurosis,” Genomics, vol. 88, no. 3, pp. 293–301,
2006.
[28] K.Narfstr¨ om,E.Bjerk˚ as,andB.Ekesten,“Visualimpairment,”
inSmall Animal Ophthalmology, aProblem OrientedApproach,
R. L. Peiﬀer and S. M. Petersen-Jones, Eds., pp. 85–165,
Saunders, 2nd edition, 2000.
[29] S. Rozen and H. Skaletsky, “Primer3 on the WWW for general
users and for biologist programmers,” Methods in Molecular
Biology, vol. 132, pp. 365–386, 2000.
[30] K. Narfstr¨ o m ,B .E k e s t e n ,S .G .R o s o l e n ,B .M .S p i e s s ,C .L .
Percicot, and R. Ofri, “Guidelines for clinical electroretinogra-
phy in the dog,” Documenta Ophthalmologica, vol. 105, no. 2,
pp. 83–92, 2002.
[31] R. Guyon, S. E. Pearce-Kelling, C. J. Zeiss, G. M. Acland, and
G. D. Aguirre, “Analysis of six candidate genes as potential
modiﬁers of disease expression in canine XLPRA1, a model
for human X-linked retinitis pigmentosa,” Molecular Vision,
vol. 13, pp. 1094–1105, 2007.
[32] N. Udar, S. Yelchits, M. Chalukya et al., “Identiﬁcation of
GUCY2D gene mutations in CORD5 families and evidence of
incomplete penetrance,” Human Mutation,v o l .2 1 ,n o .2 ,p p .
170–171, 2003.
[33] K. Yagasaki and S. G. Jacobson, “Cone-rod dystrophy. Phe-
notypic diversity by retinal function testing,” Archives of
Ophthalmology, vol. 107, no. 5, pp. 701–708, 1989.
[34] K.Miyadera,K.Kato,J.Aguirre-Hern´ andezetal.,“Phenotypic
variation and genotype-phenotype discordance in canine
cone-rod dystrophy with an RPGRIP1 mutation,” Molecular
Vision, vol. 15, pp. 2287–2305, 2009.
[35] O. Goldstein, J. G. Mezey, A. R. Boyko et al., “An ADAM9
mutation in canine cone-rod dystrophy 3 establishes homol-
ogy with human cone-rod dystrophy 9,” Molecular Vision, vol.
16, pp. 1549–1569, 2010.
[36] G. Dekomien, C. Vollrath, E. Petrasch-Parwez et al., “Pro-
gressive retinal atrophy in Schapendoes dogs: mutation of the
newly identiﬁed CCDC66 gene,” Neurogenetics, vol. 11, no. 2,
pp. 163–174, 2010.
[37] D. J. Sidjanin, J. K. Lowe, J. L. McElwee et al., “Canine CNGB3
mutations establish cone degeneration as orthologous to the
human achromatopsia locus ACHM3,” Human Molecular
Genetics, vol. 11, no. 16, pp. 1823–1833, 2002.
[38] A. V. Kukekova, O. Goldstein, J. L. Johnson et al., “Canine
RD3 mutation establishes rod-cone dysplasia type 2 (rcd2) as
ortholog of human and murine rd3,” Mammalian Genome,
vol. 20, no. 2, pp. 109–123, 2009.
[39] J. W. Kijas, A. V. Cideciyan, T. S. Aleman et al., “Naturally
occurring rhodopsin mutation in the dog causes retinal
dysfunction and degeneration mimicking human dominant
retinitis pigmentosa,” Proceedings of the National Academy of
SciencesoftheUnitedStatesofAmerica,vol.99,no.9,pp.6328–
6333, 2002.
[40] A. Veske, S. E. G. Nilsson, K. Narfstr¨ om, and A. Gal, “Retinal
dystrophy of Swedish briard/briard-beagle dogs is due to a 4-
bp deletion in RPE65,” Genomics, vol. 57, no. 1, pp. 57–61,
1999.12 Stem Cells International
[41] K. E. Guziewicz, B. Zangerl, S. J. Lindauer et al., “Bestrophin
gene mutations cause canine multifocal retinopathy: a novel
animal model for best disease,” Investigative Ophthalmology
and Visual Science, vol. 48, no. 5, pp. 1959–1967, 2007.
[42] M.L.Suber,S.J.Pittler,N.Qinetal.,“Irishsetterdogsaﬀected
with rod/cone dysplasia contain a nonsense mutation in the
rod cGMP phosphodiesterase β-subunit gene,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 90, no. 9, pp. 3968–3972, 1993.
[43] S. M. Petersen-Jones, D. D. Entz, and D. R. Sargan, “cGMP
phosphodiesterase-α mutation causes progressive retinal atro-
phy in the Cardigan Welsh corgi dog,” Investigative Ophthal-
mology and Visual Science, vol. 40, no. 8, pp. 1637–1644, 1999.
[ 4 4 ]Q .Z h a n g ,G .M .A c l a n d ,C .J .P a r s h a l l ,J .H a s k e l l ,K .R a y ,
and G. D. Aguirre, “Characterization of canine photoreceptor
phosducin cDNA and identiﬁcation of a sequence variant in
dogs with photoreceptor dysplasia,” Gene, vol. 215, no. 2, pp.
231–239, 1998.
[45] G. M. Acland, G. D. Aguirre, J. Ray et al., “Gene therapy
restores vision in a canine model of childhood blindness,”
Nature Genetics, vol. 28, no. 1, pp. 92–95, 2001.
[46] A. M. Maguire, K. A. High, A. Auricchio et al., “Age-
dependenteﬀectsofRPE65genetherapyforLeber’scongenital
amaurosis: a phase 1 dose-escalation trial,” The Lancet, vol.
374, no. 9701, pp. 1597–1605, 2009.
[47] F. Simonelli, A. M. Maguire, F. Testa et al., “Gene therapy for
leber’s congenital amaurosis is safe and eﬀective through 1.5
years after vector administration,” Molecular Therapy, vol. 18,
no. 3, pp. 643–650, 2010.
[48] R. Ofri and K. Narfstr¨ om, “Light at the end of the tunnel?
Advances in the understanding and treatment of glaucoma
and inherited retinal degeneration,” Veterinary Journal, vol.
174, no. 1, pp. 10–22, 2007.